Skip to main content
Fig. 1 | Journal of Neuroinflammation

Fig. 1

From: GPR110 (ADGRF1) mediates anti-inflammatory effects of N-docosahexaenoylethanolamine

Fig. 1

Anti-inflammatory effects of synaptamide in vivo require GPR110 receptor. Wild-type (WT) and GPR110 knock-out (KO) C57BL/6 mice (n = 3 for each group) were treated with synaptamide (5 mg/kg, i.p.) following LPS injection (1 mg/kg, i.p.), and brain and blood samples were collected to determine LPS-induced gene or protein expression at 2 and/or 24 h. The cytokine/chemokine mRNA expression in the brain was determined by qPCR at 2 h after LPS/synaptamide injection (a). The cytokine protein levels in blood were determined by ELISA at 2 and 24 h after LPS/synaptamide injection (b). Brain sections (30-μm-thick) were prepared 24 h after LPS/synaptamide injection and immunostained for Iba-1, and fluorescence microscopic images of the corpus callosum (CC) and hippocampus (HP) are presented along with quantification results of Iba-1 (c). The Iba-1 protein levels are shown by Western blot analysis of the whole brain extract (d). The cytokine protein levels in the blood were determined by ELISA at 2 and 24 h after LPS/synaptamide injection (c). Values are presented as mean ± SEM (n = 3) representing two independent experiments. ns, the difference of means is not statistically significant

Back to article page